Background The long pentraxin PTX3 is a key component of the humoral arm of innate immunity related to sepsis severity and mortality. We evaluated the clinical and prognostic significance of circulating PTX3 in the largest cohort ever reported of patients with severe sepsis or septic shock.
Introduction
Despite recent improvements in their diagnosis and treatment, the incidence of severe sepsis and septic shock in hospitalized patients, as well as their outcomes, remains unacceptably high [1] . Considering the variety of clinical phenotypes of severe sepsis and septic shock, a more accurate understanding of the underlying scenarios of the pathobiology of these clinical conditions would allow better targeted therapeutic strategies [2] . In this context, circulating biomarkers may improve early recognition and risk stratification, and therefore a targeted selection and monitoring of appropriate therapies [3] .
The long pentraxin 3 (PTX3) is a key component of the humoral arm of the innate immune response. Primary pro-inflammatory signals (bacterial components, pathogen-associated molecular patterns, damage-associated molecular patterns, IL-1, TNF-alpha) [4] induce the synthesis and release of PTX3 in various cell types such as endothelial cells, polymorphonuclear leucocytes (PMN) and monocytes/macrophages [5] . On account of its specific involvement in the immune system and inflammatory processes, and as it can be measured in blood, PTX3 has been characterized as a biomarker of disease severity and outcomes in different cardiovascular diseases, malignancies and specific infections [6] [7] [8] [9] [10] [11] . Since the first report [12] , several studies have focused on the roles of elevated circulating PTX3 in sepsis and related complications such as shock. A recent systematic review of 11 studies concluded that circulating PTX3 has solid prognostic value in sepsis and correlates with organ dysfunction, but with limited specificity [8] . However, in most of these studies, patients with severe sepsis and septic shock (for whom early stratification and selection of more aggressive treatments could be vital) were a minority, as compared to the patients with less severe conditions (infection + systemic inflammatory reaction syndrome, SIRS).
This study aimed at verifying, on a large scale, the prognostic and clinical value of circulating PTX3 in patients with severe sepsis or septic shock, previously reported in smaller and heterogeneous cohorts of critically ill patients [13] [14] [15] [16] . We assayed PTX3 in a large population of patients with severe sepsis and septic shock, enrolled in the ALBIOS trial [17] to address the following issues: first, do single or serial measurements of PTX3 have independent prognostic value? Second, are circulating PTX3 levels related with ongoing or future organ dysfunctions? Third, as the ALBIOS trial tested the efficacy of albumin replacement, and human albumin may have antiinflammatory activity, does albumin given for fluid resuscitation affect circulating PTX3?
Materials and methods

Study design
The Albumin Italian Outcome Sepsis (ALBIOS) trial was a multicentre, open-label, randomized, controlled trial on 1818 patients with severe sepsis or septic shock admitted to 100 Italian intensive care units (ICUs). Patients were randomly assigned to receive either 20% albumin and crystalloids or crystalloids alone for fluid resuscitation, from randomization until day 28 or discharge from the ICU, whichever came first. Albumin was targeted to achieve serum level of 30 g/L or more. Study design, inclusion and exclusion criteria, and main results have been published elsewhere [17] . The study was compliant with the 1975 Declaration of Helsinki as revised in 2008, and approved first by the Institutional Review Board of the Fondazione IRCCS Ca' Granda -Ospedale Maggiore Policlinico, Milan, Italy (coordinating centre), and subsequently by the institutional review boards of all the other centres. Written informed consent or deferred consent was obtained from each participant.
Sample collection and PTX3 measurement PTX3 was measured in 958 patients from the 40 centres that participated in a predefined biomarkers substudy [18] . Venous blood samples were serially collected 1, 2 and 7 days after study enrolment (or at ICU discharge, whichever came first), centrifuged and EDTA plasma was shipped on dry ice to a central repository and stored at À70°C until required. PTX3 was assayed, as previously described [19] , with sandwich ELISA (detection limit 0Á1 ng/mL, interassay variability from 8% to 10%) developed in-house, by personnel blind to patients' characteristics. A pool of plasma from healthy subjects was assayed in each analytical session with PTX3 of 1Á57 AE 0Á48 ng/mL (mean AE SD; CV 10%), in agreement with reported data for healthy subjects [20] . PTX3 was measured in 93% and 83% of the survivors on days 2 and 7, respectively.
Definitions
Severe sepsis was defined as a proved or suspected infection in at least one site, two or more signs of systemic inflammatory reaction and at least one severe, acute sepsis-related organ dysfunction [21] . Organ function was assessed on a daily basis with the use of the Sequential Organ Failure Assessment (SOFA) score [22] , which rates for each of five organ subcomponents (respiratory, coagulation, liver, cardiovascular and renal systems) from 0 to 4, with higher scores indicating a greater degree of organ dysfunction. A cardiovascular SOFA score of 3 or 4 defines the presence of any dosages of either noradrenaline or adrenaline, or a higher dosage of dopamine (greater than 5Á0 lg/kg/min) to sustain mean arterial pressure. Septic shock at the time of randomization was defined as severe sepsis with a score of 3 or 4 for the cardiovascular component of the SOFA score [23] . New organ failures were defined as a change in each SOFA component during the study, to 3 or 4 from a baseline of 0, 1 or 2. Acute kidney injury was defined according to the risk, injury, failure, loss and end-stage kidney injury (RIFLE) criteria [24] , based on the daily incremental increases in serum creatinine from baseline. Clinical resolution of the primary infection, if any, was established by the treating physician according to standard clinical and microbiological findings. Acquired secondary infections were defined as new infections other than the primary infection responsible for the development of severe sepsis, arising during the study, based on microbiological and clinical assessments and evaluated by the treating physician. Immunosuppression at enrolment was defined as previous pharmacological therapies or coexistent disease reducing the reactivity of the immune system towards an infection. Microorganism susceptibility to antibiotics was defined by a local microbiologist, unaware of the allocation group or treatment.
Statistical methods
Categorical variables are presented as proportions, and continuous variables as means (standard deviation) or medians (Q1-Q3), as appropriate. Differences in clinical characteristics according to tertiles of PTX3 concentration were compared by the chi-square test or Fisher's exact test for categorical variables; for continuous variables, analysis of variance (ANOVA) or nonparametric Kruskal-Wallis test was adopted. For all analyses, PTX3 levels were transformed into the natural logarithm to satisfy the assumptions required by the models. We did multivariable linear regression analysis to identify the baseline characteristics independently associated with higher concentrations of PTX3 on day 1.
Repeated-measures ANOVA for log-transformed PTX3 was used to assess the treatment effect over time in the overall population, and in the subgroups of patients with severe sepsis with or without shock. All measurements available at each time point for each patient were considered.
The relationship of PTX3 concentrations at each time (days 1, 2 and 7) with 90-day mortality was first described by median PTX3 levels (Q1-Q3) and analysed by one-way ANOVA. Secondly, a univariate modified Poisson regression model was adopted to evaluate the prognostic value of PTX3, considered as a continuous variable. This model, indicated in case of a common outcomes (incidence > 10%), gives a direct estimate of the relative risk (RR) with robust estimator for the variance. Finally, we adopted the multivariable modified Poisson regression model to evaluate the independent prognostic value of PTX3, accounting for the variables associated with the outcome. In addition to clinical variables, we also included into the multivariable models a cardiac biomarker (high-sensitive cardiac troponin T, hs-cTnT), as well as an inflammatory biomarker (presepsin), previously investigated [18, 25] , having independent prognostic values. Kaplan-Meier survival analysis was performed by tertiles of PTX3 concentrations on days 1, 2 and 7 and compared by the log-rank test. Normally distributed changes in PTX3 concentrations on days 2 and day 7 from day 1 were expressed as the difference in log-transformed levels and compared by ANOVA between survivors and patients who died. Unadjusted and adjusted modified Poisson regression models were generated to assess potential associations between changes in PTX3 concentrations over time and 90-day mortality. All covariates in the multivariable models were measured at baseline and significantly associated with the outcome. Similarly, the prognostic value of PTX3 for the clinical outcomes was assessed by modified Poisson regression for categorical variables and by multivariable linear regression for continuous variables. A two-sided P value lower than 0Á05 was deemed significant. All statistical analyses were performed with SAS software 9.3 (SAS Institute, Cary, NC, USA). Reporting of the study conforms to CONSORT-revised and the broader EQUATOR guidelines [26] .
Results
Clinical characteristics and PTX3 concentrations
The concentration of PTX3 on day 1 after randomization in the overall cohort of patients was elevated, all patients having higher than normal levels (> 2 ng/mL) [20] . PTX3 levels on day 1 were associated with several demographic, clinical, hemodynamic and laboratory variables ( Table 1) .
Multiple linear regression analysis showed the strongest association of higher PTX3 concentrations with the following variables, by decreasing order of t-value: higher serum lactate (beta coefficient = 0Á090 AE 0Á016, P < 0Á0001), shorter time between enrolment and sampling (À0Á026 AE 0Á006, P < 0Á0001), higher heart rate (0Á008 AE 0Á002, P < 0Á0001), presence of positive blood culture (0Á35 AE 0Á08, P < 0Á0001), lower body mass index (À0Á027 AE 0Á007, P < 0Á0001), higher SAPSII score (0Á011 AE 0Á003, P = 0Á0005), higher haemoglobin (0Á066 AE 0Á019, P = 0Á0007), higher SOFA score (0Á0 AE 0Á02, P = 0Á03), lower white blood cell count (À0Á009 AE 0Á004, P = 0Á04) and higher serum creatinine (0Á06 AE 0Á03, P = 0Á04).
The concentration of PTX3 on day 1 paralleled the degree of the severity of organ dysfunctions, as denoted by the SOFA score ( Figure S1 ), and the number of prevalent organ failures at enrolment ( Figure S2 ). The PTX3 concentration was significantly higher in patients with urinary tract infection than those without urinary tract involvement, and lower in patients with lung infections than those without (Table S1 ). No significant association was observed in patients with specific infections originating in the abdomen or other sites. Patients with Gramnegative or Gram-positive infections had similar PTX3 levels (P = 0Á28 for site culture). Patients with depressed immune system function on day 1 (n = 124) had higher PTX3 concentrations on day 1 (114Á5 [40Á4-229Á2]) than those without (66Á0 [31Á8-181Á7], P = 0Á002). Patients who had lower circulating levels of PTX3 on day 1 were more likely to achieve hemodynamic stability within the first 24 h than those with higher levels (in particular, mean arterial pressure 65 mm Hg or more, or serum lactate lower than 2 mM). Accordingly, reduced use of vasoactive drugs was associated with lower levels of PTX3 on day 1 (Table S2) . Finally, higher PTX3 levels on day 1 appeared to be associated with a greater probability of developing novel organ failures during the study, in particular coagulation, cardiovascular and renal (Fig. 1 ).
PTX3 levels during ICU stay
Patients with shock had higher PTX3 concentration than those without (P < 0Á0001) at all time points (days 1, 2 and 7), and it Table 1 Clinical characteristics according to baseline PTX3 concentration
Body mass index
Reason for admission to ICU appeared to drop more over time in the former than in the latter patients (P for interaction time by shock = 0Á0004; Fig. 2a ). Circulating PTX3 concentration was also consistently higher in patients randomized to crystalloids than in those assigned albumin (P = 0Á03), but this difference was limited to patients with septic shock (P = 0Á005), whereas there was no treatment effect in those with severe sepsis without shock (P = 0Á82). Of note, the time courses were not different in either subgroup (interaction time by treatment P = 0Á90 and 0Á55, in severe sepsis without shock and in septic shock, respectively) (Fig. 2b,  c ).
PTX3 and clinical outcomes
All-cause mortality in the ICU and at 90 days was, respectively, 26Á4% and 39Á0%. Clinical characteristics of the study population according to 90-day mortality are shown in Table S3 . Plasma concentrations of PTX3 were consistently higher at each time point (days 1, 2 and 7) in those who died than in survivors after 90 days (P < 0Á0001, Figure S3 ). Survival analysis at 90 days with Kaplan-Meier curves by tertiles of PTX3 concentration on days 1, 2 and 7 is shown in Fig. 3 . There was a graded increase in the risk of death across tertiles of PTX3 levels (log-rank test: P < 0Á0001 for the three time points). However, after adjustment for all confounders, including the circulating biomarkers hs-cTnT and presepsin, neither the PTX3 . Repeated-measures analysis of variance was performed on log-transformed concentrations. In all patients: time P < 0Á0001, shock P < 0Á0001, interaction time by shock P = 0Á0004; in patients with severe sepsis without shock: time P < 0Á0001, treatment P = 0Á82, interaction time by treatment P = 0Á90; in patients with septic shock: time P < 0Á0001, treatment P = 0Á005, interaction time by treatment P = 0Á55.
concentration on day 1 nor on day 2 was associated with increased 90-day mortality, and only PTX3 on day 7 showed a significant, independent predictive value (HR = 1Á13 [1Á01-1Á26], P = 0Á04). Finally, although higher PTX3 levels on day 1 appeared to be associated with clinical outcomes assessed at post hoc analyses, after adjustment for clinical and laboratory variables, the only significant association was between PTX3 concentration on day 1 and acute kidney injury (Table S4) . We then evaluated the predictive value of the changes of PTX3 concentrations from day 1 to day 2 or from day 1 to day 7. The prognostic models included demographic and clinical variables associated with 90-day mortality, and were also adjusted for baseline PTX3 concentrations. The drop over the first 2 days of PTX3 was more marked in survivors (À0Á66 AE 0Á87 on a log scale) than in the patients who died (À0Á45 AE 0Á84, P = 0Á0007), with similar differences in patients with or without shock. Changes in PTX3 from day 1 to day 2 and from day 1 to day 7 ( Figure S4 ) were independently associated with 90-day mortality, after adjustment for clinical variables and two circulating biomarkers of inflammation and cardiac injury, presepsin and high-sensitive cardiac troponin T (Fig. 4) . PTX3 had a significant, but limited prognostic discrimination with area under the receiver operating characteristic (ROC) curves for 90-day mortality comprised between 0Á57 and 0Á60 (data not shown). Finally, there was no significant interaction between PTX3 concentration on day 1 and treatment allocation (albumin or crystalloids) on 90-day mortality (P = 0Á31).
Discussion
In a large cohort of well-characterized patients with severe sepsis or septic shock in the ALBIOS trial: (i) the PTX3 concentrations on day 1 were extremely elevated, compared with other clinical conditions (cardiovascular diseases, cancer, autoimmune diseases) and mostly associated with hyperlactatemia, tachycardia and lower body mass index (BMI), (ii) higher PTX3 on day 1 predicted incident new organ failures, (iii) a slow decrease in PTX3, but not absolute levels on days 1 and 2, was independently associated with higher mortality and (iv) patients with septic shock assigned to albumin and crystalloids had lower PTX3 levels through days 1-7 as compared to those randomized to crystalloids alone. In addition, higher PTX3 on day 1 was associated with greater hemodynamic instability, as indicated by a smaller proportion of patients with Figure 3 Kaplan-Meier survival curves for 90-day mortality by tertiles of PTX3 on days 1, 2 and 7. The number of patients at risk and events are shown below the curves. Tertiles of PTX3: day 1 (lower < 41Á1, mid 41Á1-137Á5, upper > 137Á5 ng/mL), day 2 (lower < 25Á3, mid 25Á3-54Á6, upper > 54Á6 ng/mL), day 3 (lower < 11Á8, mid 11Á8-26Á9, upper > 26Á9 ng/mL). P for logrank test < 0Á0001 for all.
adequate mean arterial pressure, or a greater need for vasoactive drugs during the first 24 h. These findings may explain the close relationship between PTX3 and the number and degree of organ dysfunctions, as indicated by the SOFA scores for all its components.
Some of the findings of the current study confirm those previously reported [13] , such as the higher concentrations of circulating PTX3 in patients with urinary tract infections, and the persistent higher PTX3 levels in nonsurvivors compared to survivors. Nonetheless, the 10-fold larger sample size and the presence of two randomly assigned strategies of fluid therapy (crystalloids with or without human albumin) meant we could confidently assess the behaviour of PTX3 in different subgroups, as well the effect of albumin.
The strong associations of higher PTX3 and incident cardiovascular or renal failure are consistent with previous evidence of PTX3 involvement in acute coronary syndromes/acute myocardial infarction, on one side [6, 27] , and in chronic kidney disease on the other [28] . In experimental models of myocardial infarction and coronary artery disease, PTX3 appeared to have a significant protective role in the pathogenesis of myocardial injury [29, 30] . Similarly, lower levels of circulating PTX3 appeared to be also associated with enhanced neutrophil recruitment, cell death, activation of coagulation cascades and inflammatory responses in the lung in an experimental model of acute lung injury [31, 32] . In different models of tissue repair, PTX3 deficiency was associated with greater deposition and persistence of fibrin [33] . These findings increase the difficulty of interpreting high circulating levels of PTX3 as a marker of injury or of a protective response of the body. They further highlight the complexity of the pathogenesis of sepsis and its difference from other diseases with putative inflammatory involvement, with appreciable imbalances between excessive activation of the immune system and an immune paralysis state [2] . Along this line of reasoning, the higher PTX3 levels in patients with immunosuppression at the time of developing sepsis may be interpreted as an extreme, although ineffective, defensive response. It is worth mentioning that this 'response' has been shown to be orchestrated by rapid release of PTX3 stored in PMN followed by an increase in its synthesis [34, 35] . Although we did not do a differential leucocyte count, it is conceivable that the lower levels of PTX3 on day 1, together with higher counts of circulating leucocytes, may indicate lower activation of PMN and ultimately less severe disease.
Lower PTX3 levels on day 1 were also associated with a greater probability of achieving hemodynamic stability during the first 24 h of treatment, suggesting a possible role of PTX3 in the pathogenesis of microvascular alterations and endothelial dysfunction, as previously reported [36] .
In relation to the prognostic value of early measurements of plasma PTX3, we found that changes in PTX3 over time, but not its single levels, independently predicted mortality, confirming preliminary findings in a smaller cohort of septic patients [13] , and data from patients with chronic heart failure [7] . The prognostic value of PTX3 changes remained significant also when considering variations during the early phases of severe sepsis or septic shock, that is from day 1 to day 2. These results strongly suggest the clinical utility of serial monitoring of Figure 4 Modified Poisson regression models for 90-day mortality by changes in PTX3 concentrations over time. The relation between continuous changes in PTX3 concentrations between days 1, 2 or 7 was estimated with simple or adjusted modified Poisson regression models. Multivariable model 1 included the log-transformed concentration of PTX3 on day 1, age, sex, body mass index, reason for ICU admission, SAPS II and SOFA scores, pre-existing conditions (liver disease, chronic obstructive pulmonary disease, chronic renal failure, immunodeficiency, congestive or ischaemic heart disease), mean arterial pressure, fraction of inspired oxygen FiO 2 , diuresis, serum concentrations of lactate, albumin, bilirubin and creatinine, blood platelets, septic shock at randomization, mechanical ventilation, antibiotics at randomization, positive blood culture. Model 2 = model 1 + plasma concentrations of presepsin and high-sensitive cardiac troponin T on day 1. circulating PTX3, particularly during the early, 'active' phase of this syndrome, when monitoring the response to therapy is so important.
In the ALBIOS trial, patients were randomized to receive either albumin and crystalloids or crystalloids alone for volume replacement [17] . Albumin replacement did not improve survival at 28 and 90 days in the overall population, but provided slight, significant haemodynamic advantages, as well as a survival advantage in the subgroup of patients with septic shock [17, 37] . In the current study, PTX3 concentrations of patients with septic shock receiving albumin were significantly lower during the first 7 days than in patients receiving only crystalloids, whereas there was no significant treatment effect in patients with severe sepsis without shock. In addition, there was no significant interaction on PTX3 concentration between time and the treatment. Nonetheless, the consistently lower levels of PTX3 in the first 7 days, in association with albumin replacement, suggest an effect of exogenous albumin on circulating PTX3, either indirect or direct. First, a low PTX3 concentration in the albumin group may be simply an indirect marker of its anti-inflammatory effect [38] , with a consequent potential improvement of organ function [39] . Second, although to the best of our knowledge this has never been investigated, we may hypothesize a direct binding of albumin to the PTX3 molecule, considering the extensive ligand ability of human albumin [40] , leading to reduced PTX3 levels in patients with higher serum albumin concentrations.
Finally, as the antioxidant activity of human albumin, related to the free cysteine residue [40] , reduces overall plasma oxidative stress [38] , conceivably higher serum albumin concentrations protect PTX3 from redox-sensitive oligomerization [16] , leading to faster clearance of PTX3 while in the monomeric state, as compared to patients not receiving albumin.
The present study has some limitations. First, it did not include all the patients enrolled in the ALBIOS trial, as only a subgroup of the participating centres was involved in the biomarker substudy. Nonetheless, in the biomarker substudy, these centres enrolled the majority of the patients randomized in the main trial, guaranteeing representativeness of the disease and the entire cohort investigated. Second, as ALBIOS was a pragmatic trial, the first blood sample was drawn not at study enrolment, which would have created an undue workload in a critical phase of the trial (and patient treatment), but on average, 20 AE 6 h later (on the morning of day 1), after completion of the diagnostic workup, optimization of treatments and starting study treatment. Therefore, PTX3 levels on day 1 may have been affected by early study treatment. Nonetheless, the availability of plasma collections at further time points allows the evaluation of the time-course of the biomarkers with reasonable accuracy during the first, most critical phase of the clinical treatment.
Conclusions
The present study confirms in a large cohort of patients enrolled in a controlled, multicentre randomized clinical trial that circulating PTX3 concentrations are elevated in severe sepsis and even higher in septic shock. They peak within the first day after diagnosis, and they tightly correlate with prevalent and incident organ failures. Impaired normalization of these levels in the first few days independently predicts unfavourable clinical outcomes (hemodynamic instability, multiorgan dysfunction and failure) that may ultimately compromise survival. The lower levels of PTX3 in patients with septic shock treated with albumin are consistent with the survival benefit observed in this subgroup [17] .
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